BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC raised its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 18.6% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 4,223 shares of the medical equipment provider’s stock after acquiring an additional 663 shares during the period. GAMMA Investing LLC’s holdings in BioLife Solutions were worth $96,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Rhumbline Advisers lifted its stake in shares of BioLife Solutions by 0.7% in the 1st quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider’s stock worth $1,901,000 after acquiring an additional 566 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of BioLife Solutions by 13.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider’s stock worth $1,835,000 after acquiring an additional 8,258 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of BioLife Solutions in the 4th quarter worth $31,000. Point72 Asset Management L.P. acquired a new stake in shares of BioLife Solutions in the 4th quarter worth $11,113,000. Finally, ProShare Advisors LLC acquired a new stake in shares of BioLife Solutions in the 4th quarter worth $282,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Insider Buying and Selling at BioLife Solutions

In other news, major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $23.80, for a total value of $23,800,000.00. Following the completion of the transaction, the insider owned 7,707,165 shares of the company’s stock, valued at $183,430,527. The trade was a 11.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 1,007,436 shares of company stock valued at $23,965,366 over the last ninety days. Insiders own 2.20% of the company’s stock.

BioLife Solutions Stock Up 2.2%

BLFS stock opened at $23.26 on Monday. The company has a current ratio of 4.73, a quick ratio of 3.74 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.10 billion, a P/E ratio of -80.20 and a beta of 1.79. The company’s 50-day moving average price is $22.55 and its 200 day moving average price is $24.45. BioLife Solutions, Inc. has a 52 week low of $18.70 and a 52 week high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. The company had revenue of $23.94 million during the quarter, compared to analysts’ expectations of $22.22 million. BioLife Solutions had a negative net margin of 11.81% and a negative return on equity of 0.66%. On average, research analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BLFS has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Tuesday, May 13th. Wall Street Zen downgraded shares of BioLife Solutions from a “hold” rating to a “sell” rating in a report on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat, BioLife Solutions has a consensus rating of “Moderate Buy” and an average target price of $31.17.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.